On May 24, 2016 Ignyta, Inc. (Nasdaq: RXDX), a precision oncology biotechnology company, reported the publication of an abstract for a poster session at the 2016 Annual Meeting of the American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) in Chicago, Illinois (Press release, Ignyta, MAY 24, 2016, View Source [SID:1234512753]). The abstract relates to the results of the Phase 1 clinical trial of RXDX-105, the company’s orally available, small molecule multikinase inhibitor with potent activity against such targets as RET and BRAF. The poster session will be held on Sunday, June 5, 2016.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"We are honored that the ASCO (Free ASCO Whitepaper) Scientific Program Committee has selected the abstract describing exciting data from our Phase 1 clinical trial of RXDX-105 for a poster presentation," said Pratik Multani, M.D., Chief Medical Officer of Ignyta. "We are looking forward to sharing updated data from this clinical trial in this prestigious scientific forum."
Details of the presentation are as follows:
Title:
A phase 1 dose escalation study of RXDX-105, an oral RET and BRAF inhibitor, in patients with advanced solid tumors. (Abstract number 2574, Poster number 274)
Date/time: Sunday, June 5, 2016, 8:00 AM – 11:30 AM, Central time